CORE POSITIONING

Current ADCs are constrained by dose-limiting toxicities—particularly hematological toxicity—suboptimal activity in resistant tumors, and an increasingly crowded target landscape. Skymab addresses these challenges through innovation in both ADC chemistry and target biology.